Cargando…

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer

Taselisib is a potent and selective phosphatidylinositide 3‐kinase (PI3K) inhibitor. The present article reports the first study of taselisib administration in Japanese patients. The aim of this 2‐stage, phase I, multicenter, open‐label, dose‐escalation study was to evaluate the safety, pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Kenji, Kodaira, Makoto, Shimizu, Chikako, Yonemori, Kan, Yunokawa, Mayu, Shimomura, Akihiko, Kobayashi, Takayuki, Nakano, Kenji, Tomomatsu, Junichi, Ito, Yoshinori, Tanaka, Jun, Kuriki, Hiroshi, Gu, Zhaodi, Takahashi, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980117/ https://www.ncbi.nlm.nih.gov/pubmed/29500843 http://dx.doi.org/10.1111/cas.13561

Ejemplares similares

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

TERT promoter hotspot mutations in breast cancer
por: Shimoi, Tatsunori, et al.
Publicado: (2017)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Primary Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
por: Harano, Kenichi, et al.
Publicado: (2012)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
por: Tamura, Kenji, et al.
Publicado: (2016)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial
por: Sato, Yasuyoshi, et al.
Publicado: (2020)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution
por: Marshall, Shoko, et al.
Publicado: (2018)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients
por: Fukuda, Naoki, et al.
Publicado: (2020)

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
por: Nakano, Kenji, et al.
Publicado: (2016)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Use of Cox's Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
por: Asano, Junichi, et al.
Publicado: (2013)

Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
por: Tamura, Kenji, et al.
Publicado: (2023)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
por: Takahashi, Shunji, et al.
Publicado: (2021)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
por: Ohmoto, Akihiro, et al.
Publicado: (2021)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
por: Fujiwara, Yutaka, et al.
Publicado: (2021)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9u22f6nr12g53759rm9df1kom1